Induction and Consolidation With Elotuzumab Before and After Peripheral Stem Cell Autologous Graft in Elderly Patients With Multiple Myeloma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Thalidomide (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IFM2016-03
- 15 Jul 2019 Status changed from not yet recruiting to withdrawn prior to enrolment, as per the Investigator decision in accordance with the promotor
- 09 May 2018 Planned End Date changed from 1 Jan 2023 to 1 May 2023.
- 09 May 2018 Planned primary completion date changed from 1 Jan 2023 to 1 May 2023.